Literature DB >> 29475909

Inhibition of Systemic Hyaluronan Synthesis Exacerbates Murine Hepatic Carcinogenesis.

Kenichiro Mikami1, Tetsu Endo2, Naoya Sawada2, G O Igarashi2, Masayo Kimura2, Hirotake Sakuraba2, Shinsaku Fukuda2.   

Abstract

BACKGROUND/AIM: Hyaluronan (HA) is used as a biomarker of liver fibrosis, which is a key risk factor for the development of hepatocellular carcinoma (HCC). We examined the effects of prolonged pharmacological inhibition of HA synthesis on liver carcinogenesis.
MATERIALS AND METHODS: Liver tumors were induced in mice by administering 0.03% thioacetamide (TAA) in drinking water over a 12-month period. Animals simultaneously received either a diet containing of an inhibitor of HA synthesis [4-methylumbelliferone (4-MU)], or a control diet.
RESULTS: Addition of 4-MU resulted in a significantly higher number of tumors compared to TAA treatment alone. Moreover, addition of 4-MU resulted in a dose-dependent increase in maximum tumor size.
CONCLUSION: While local HA suppression has been shown to have an inhibitory effect on HCC in vitro and in tumor cell implantation experiments, the present results indicate that systemic inhibition of HA synthesis by 4-MU supplementation facilitates hepatic carcinogenesis in vivo. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  4-methylumelliferone; Hepatocellular carcinoma; hyaluronan

Mesh:

Substances:

Year:  2018        PMID: 29475909      PMCID: PMC5905194          DOI: 10.21873/invivo.11234

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  38 in total

Review 1.  Hyaluronan: from extracellular glue to pericellular cue.

Authors:  Bryan P Toole
Journal:  Nat Rev Cancer       Date:  2004-07       Impact factor: 60.716

Review 2.  Common extracellular matrix regulation of myeloid cell activity in the bone marrow and tumor microenvironments.

Authors:  Sabina Sangaletti; Claudia Chiodoni; Claudio Tripodo; Mario P Colombo
Journal:  Cancer Immunol Immunother       Date:  2017-05-13       Impact factor: 6.968

3.  Relationship between hyaluronan production and metastatic potential of mouse mammary carcinoma cells.

Authors:  N Itano; T Sawai; O Miyaishi; K Kimata
Journal:  Cancer Res       Date:  1999-05-15       Impact factor: 12.701

Review 4.  Comparison of hepatocellular carcinoma in Eastern versus Western populations.

Authors:  Su Pin Choo; Wan Ling Tan; Brian K P Goh; Wai Meng Tai; Andrew X Zhu
Journal:  Cancer       Date:  2016-09-13       Impact factor: 6.860

Review 5.  Nutrition and immunity in cancer.

Authors:  Roxana Valdés-Ramos; Alejandra D Benítez-Arciniega
Journal:  Br J Nutr       Date:  2007-10       Impact factor: 3.718

Review 6.  The organizing principle: microenvironmental influences in the normal and malignant breast.

Authors:  Mina J Bissell; Derek C Radisky; Aylin Rizki; Valerie M Weaver; Ole W Petersen
Journal:  Differentiation       Date:  2002-12       Impact factor: 3.880

7.  Hyaluronan oligosaccharides induce CD44 cleavage and promote cell migration in CD44-expressing tumor cells.

Authors:  Kazuki N Sugahara; Toshiyuki Murai; Hitomi Nishinakamura; Hiroto Kawashima; Hideyuki Saya; Masayuki Miyasaka
Journal:  J Biol Chem       Date:  2003-06-11       Impact factor: 5.157

8.  Hyaluronan-CD44 interaction promotes growth of decidual stromal cells in human first-trimester pregnancy.

Authors:  Rui Zhu; Song-Cun Wang; Chan Sun; Yu Tao; Hai-Lan Piao; Xiao-Qiu Wang; Mei-Rong Du
Journal:  PLoS One       Date:  2013-09-19       Impact factor: 3.240

9.  Activated lymphocytes as a metabolic model for carcinogenesis.

Authors:  Andrew N Macintyre; Jeffrey C Rathmell
Journal:  Cancer Metab       Date:  2013-01-23

10.  Accumulation of small hyaluronan oligosaccharides in tumour interstitial fluid correlates with lymphatic invasion and lymph node metastasis.

Authors:  A Schmaus; S Klusmeier; M Rothley; A Dimmler; B Sipos; G Faller; W Thiele; H Allgayer; P Hohenberger; S Post; J P Sleeman
Journal:  Br J Cancer       Date:  2014-06-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.